360Dx

Cepheid Enters Rapid Syndromic Testing Space With FDA Clearance of GI Panel

The Danaher subsidiary aims to meet clinician needs for flexibility with a range of test size options for its vast installed base.

Cepheid Receives FDA Clearance for Xpert® GI Panel to Support Broad Detection of Gastrointestinal Pathogens

Cepheid announced today that it has received FDA clearance for Xpert GI Panel, a multiplex PCR test designed to provide fast ...

Polymerase Chain Reaction Market To Reach US$31.3Bn By 2033 Persistence Market Research

Polymerase Chain Reaction Market To Reach US$31.3Bn By 2033 Persistence Market Research. EINPresswire/ -- The global polymerase chain reaction (PCR) market, integral to molecular diagnostics and life ...
Medscape

Point-Of-Care Test Enhances STI Care in Emergency Department

Point-of-care testing for common sexually transmitted infections may reduce overuse of antibiotics and improve emergency ...
Infectious Disease Advisor

Point-of-Care STI Testing Reduces ED Length of Stay and Unnecessary Antibiotic Use

Point-of-care PCR testing for STIs in the ED reduced length of stay and improved antibiotic stewardship compared with central laboratory testing.
European Medical Journal

Flu Symptoms Return as Winter Viruses Rebound

After COVID-19 NPIs lifted, respiratory infections reverted toward pre pandemic seasonality, with winter peaks for RSV and Influenza A. Multiplex PCR surveillance highlighted rhinovirus dominance and ...

Mainz Biomed Provides Review of 2025 Highlights

Initiation of eAArly DETECT 2 - U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient ...
Investing

Co-diagnostics receives Australian patent for PCR testing platform

SALT LAKE CITY - Co-Diagnostics, Inc. (NASDAQ:CODX) announced Monday that the Australian Patent Office has granted the company its first patent for its point-of-care PCR testing platform. The microcap ...
Seeking Alpha

Co-Diagnostics Initiates Clinical Evaluations for Upper Respiratory Multiplex Point-of-Care Test on Co-Dx™ PCR Platform to Support Submission to the U.S. FDA

SALT LAKE CITY, Nov. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular ...